South County Business Park
215 articles with ICON
ICON plc , (NASDAQ: ICLR) (“ICON”) today announced the completion of its acquisition of PRA Health Sciences. The combined company will retain the name ICON and will bring together 38,000 employees across 47 countries, creating the world’s most advanced healthcare intelligence and clinical research organization.
Evergreen Therapeutics, Inc. Announces Agreement with ICON plc to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate
Evergreen Therapeutics, Inc. today announced a clinical service agreement with ICON plc (“ICON”) to conduct a global, multi-center Phase II clinical trial for Evergreen’s COVID-19 drug therapy candidate EG-009A.
ICON plc (NASDAQ: ICLR) (“ICON”) announced today in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc.
ICON plc to Present at the Jefferies Virtual Healthcare Conference and the William Blair 41st Growth Stock Conference
ICON plc, a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021.
ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research
The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced value to patients, customers, employees and shareholders.
Record net business wins in the quarter of $1,080 million; a book to bill of 1.42. Full year net business wins of $3.8 billion; a net book to bill of 1.38.
ICON Launches FIRECREST Safety Letters and Site Question Management Supporting Regulatory Compliance and Increasing Site Support
New solutions enable enhanced delivery, tracking and management of drug safety reporting and medical questions from sites
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting held on July 21, 2020
ICON plc, a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, announced that all resolutions at the Annual General Meeting of the Company held on July 21, 2020 were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 9, 2020 and are available on the ICON plc website.
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, reported its financial results for the fourth quarter and full year ended December 31, 2019.
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019
ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2019.
ICON Wins Multiple Awards at the 2019 Clinical and Research Excellence Awards
ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials
ICON plc announced the release of its web based patient engagement platform, to provide patients with study specific information and connectivity with the nearest investigative site.
ICON recognised for specialised services offering across product development lifecycle
2019 outlook reaffirmed with revenue guidance in the range of $2,735 - $2,835 million and earnings per share guidance in the range of $6.69 – $6.89 a year over year increase of 9.9% - 13.1%.
Developed on platform deploying rule-based automation for timely delivery of drug safety information
Announces intention to repurchase up to 1 million shares during 2019.
Software provides an integrated technology platform for adaptive clinical trials
Excluding the impact of ASC 606, record net business wins in the quarter of $600 million; a book to bill of 1.27.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.